Recent News

• 12.15.2025 - argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
• 11.18.2025 - argenx Announces Results of Extraordinary General Meeting of Shareholders
• 10.30.2025 - argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
• 10.29.2025 - argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
• 10.23.2025 - argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
• 10.15.2025 - argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
• 10.03.2025 - argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
• 10.03.2025 - argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
• 08.28.2025 - argenx to Present at Upcoming Investor Conferences

Recent Filings

• 11.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.18.2025 - EX-99.1 EX-99.1
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.30.2025 - EX-99.1 EX-99.1
• 10.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.29.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.29.2025 - EX-99.1 EX-99.1
• 10.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.15.2025 - EX-99.1 EX-99.1
• 10.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]